RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+36.75%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$1.05B
AUM Growth
+$1.05B
(+75%)
Cap. Flow
+$381M
Cap. Flow
% of AUM
36.25%
Top 10 Holdings %
Top 10 Hldgs %
71.51%
Holding
46
New
14
Increased
15
Reduced
8
Closed
8
Top Buys
| 1 |
Rocket Pharmaceuticals
RCKT
|
$258M |
| 2 |
Sarepta Therapeutics
SRPT
|
$51M |
| 3 |
AGEN
Agenus
AGEN
|
$23.5M |
| 4 |
Arrowhead Research
ARWR
|
$21M |
| 5 |
Bristol-Myers Squibb
BMY
|
$16.3M |
Top Sells
| 1 |
BioCryst Pharmaceuticals
BCRX
|
$16.6M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$13.4M |
| 3 |
OraSure Technologies
OSUR
|
$12.9M |
| 4 |
Atara Biotherapeutics
ATRA
|
$10.1M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$6.99M |
Sector Composition
| 1 | Healthcare | 93.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Rocket Pharmaceuticals
RCKT
$354M
| $258M | 24.57% | +14,969,744 | New | +$258M |
|
2
PTC Therapeutics
PTCT
$3.92B
| $112M | 10.66% | 4,137,960 +7,845 | +0.2% | +$212K |
|
|
3
Bristol-Myers Squibb
BMY
$96B
| $69.3M | 6.6% | 1,096,386 +256,934 | +31% | +$16.3M |
|
4
Regenxbio
RGNX
$451M
| $56.1M | 5.33% | 1,877,767 +316,557 | +20% | +$9.45M |
|
|
5
Sarepta Therapeutics
SRPT
$1.78B
| $51M | 4.85% | +688,271 | New | +$51M |
|
|
ACHN
6
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $50.1M | 4.77% | 13,496,902 -50,000 | -0.4% | -$186K |
|
|
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $48.1M | 4.58% | 5,029,462 -6,200 | -0.1% | -$59.3K |
|
|
AGEN
8
Agenus
AGEN
$133M
| $43.9M | 4.17% | 9,313,556 +4,983,740 | +115% | +$23.5M |
|
|
LJPC
9
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $33.4M | 3.18% | 1,122,540 +59,370 | +6% | +$1.77M |
|
|
10
Alnylam Pharmaceuticals
ALNY
$58.5B
| $29.3M | 2.79% | 246,229 -112,545 | -31% | -$13.4M |
|
|
AVXS
11
DELISTED
AveXis, Inc. Common Stock
AVXS
| $29.2M | 2.78% | 236,425 -44,817 | -16% | -$5.54M |
|
12
Arbutus Biopharma
ABUS
$711M
| $25.8M | 2.45% | 5,151,615 | – | – |
|
|
GBT
13
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $22.1M | 2.1% | 456,921 -144,762 | -24% | -$6.99M |
|
|
CORI
14
DELISTED
Corium International, Inc.
CORI
| $21.9M | 2.09% | 1,910,522 +210,869 | +12% | +$2.42M |
|
|
15
Arrowhead Research
ARWR
$3.05B
| $21M | 2% | +2,916,561 | New | +$21M |
|
16
Vericel Corp
VCEL
$1.83B
| $20.6M | 1.96% | 2,067,916 +763,115 | +58% | +$7.59M |
|
17
Masimo
MASI
$7.59B
| $20.4M | 1.94% | 232,000 +111,100 | +92% | +$9.77M |
|
18
Edwards Lifesciences
EW
$47.8B
| $20.3M | 1.93% | 145,246 +22,246 | +18% | +$3.1M |
|
|
ARMO
19
DELISTED
ARMO BioSciences, Inc. Common Stock
ARMO
| $14M | 1.33% | +413,892 | New | +$14M |
|
|
MYOK
20
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $12.7M | 1.21% | 259,670 +2,007 | +0.8% | +$97.9K |
|
21
LivaNova
LIVN
$3.08B
| $12.4M | 1.18% | +140,000 | New | +$12.4M |
|
22
uniQure
QURE
$896M
| $9.56M | 0.91% | 406,667 +3,143 | +0.8% | +$73.9K |
|
|
VIVE
23
DELISTED
VIVEVE MED INC
VIVE
| $9.36M | 0.89% | 2,557,559 +884,561 | +53% | +$3.24M |
|
|
VRAY
24
DELISTED
ViewRay, Inc.
VRAY
| $8.74M | 0.83% | 1,358,711 +10,501 | +0.8% | +$67.5K |
|
|
NVTR
25
DELISTED
Nuvectra Corporation Common Stock
NVTR
| $6.6M | 0.63% | +507,061 | New | +$6.6M |
|